Glomerulonephritis - Pipeline Review, H2 2017

Date: September 19, 2017
Pages: 157
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G53DA23E3B0EN
Leaflet:

Download PDF Leaflet

Glomerulonephritis - Pipeline Review, H2 2017
Glomerulonephritis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H2 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 5, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Glomerulonephritis - Overview
Glomerulonephritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Glomerulonephritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glomerulonephritis - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Merck KGaA
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Shire Plc
Visterra Inc
Glomerulonephritis - Drug Profiles
(irbesartan + propagermanium) - Drug Profile
abatacept - Drug Profile
ACH-4471 - Drug Profile
ACH-5228 - Drug Profile
AMY-101 - Drug Profile
atacicept - Drug Profile
avacopan - Drug Profile
AVX-002 - Drug Profile
BaxB-01 - Drug Profile
BaxG-03 - Drug Profile
belimumab - Drug Profile
blisibimod - Drug Profile
budesonide - Drug Profile
CAB-102 - Drug Profile
CCX-140 - Drug Profile
CXA-10 - Drug Profile
ERG-240 - Drug Profile
fostamatinib disodium - Drug Profile
losmapimod - Drug Profile
Monoclonal Antibodies to Inhibit ITGAM for Cardiovascular, Immunology and Kidney Diseases - Drug Profile
OMS-721 - Drug Profile
PBF-677 - Drug Profile
PF-06730512 - Drug Profile
PF-1355 - Drug Profile
Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
rituximab - Drug Profile
SHP-627 - Drug Profile
Small Molecule to Inhibit Factor D for C3 glomerulopathy and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
sparsentan - Drug Profile
Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
TM-5484 - Drug Profile
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
VAR-200 - Drug Profile
VIS-649 - Drug Profile
Glomerulonephritis - Dormant Projects
Glomerulonephritis - Discontinued Products
Glomerulonephritis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Glomerulonephritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Glomerulonephritis - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H2 2017
Glomerulonephritis - Pipeline by Biogen Inc, H2 2017
Glomerulonephritis - Pipeline by Bristol-Myers Squibb Company, H2 2017
Glomerulonephritis - Pipeline by Cellmid Ltd, H2 2017
Glomerulonephritis - Pipeline by ChemoCentryx Inc, H2 2017
Glomerulonephritis - Pipeline by Complexa Inc, H2 2017
Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017
Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2017
Glomerulonephritis - Pipeline by Merck KGaA, H2 2017
Glomerulonephritis - Pipeline by Omeros Corp, H2 2017
Glomerulonephritis - Pipeline by Pfizer Inc, H2 2017
Glomerulonephritis - Pipeline by Pharmalink AB, H2 2017
Glomerulonephritis - Pipeline by Ra Pharmaceuticals Inc, H2 2017
Glomerulonephritis - Pipeline by Retrophin Inc, H2 2017
Glomerulonephritis - Pipeline by Rigel Pharmaceuticals Inc, H2 2017
Glomerulonephritis - Pipeline by Shire Plc, H2 2017
Glomerulonephritis - Pipeline by Visterra Inc, H2 2017
Glomerulonephritis - Dormant Projects, H2 2017
Glomerulonephritis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Glomerulonephritis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Glomerulonephritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Merck KGaA
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Shire Plc
Visterra Inc
Skip to top


Otitis Media - Pipeline Review, H2 2017 US$ 2,000.00 Jul, 2017 · 72 pages

Ask Your Question

Glomerulonephritis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: